PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.46%
Revenue growth at 50-75% of META's 12.29%. Martin Whitman would worry about competitiveness or product relevance.
11.19%
Gross profit growth similar to META's 12.33%. Walter Schloss would assume both firms track common industry trends.
240.74%
EBIT growth above 1.5x META's 10.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
240.74%
Operating income growth above 1.5x META's 16.44%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
23.59%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
176.60%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
182.61%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-20.54%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-21.88%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-21.63%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-43.70%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
615.50%
10Y revenue/share CAGR at 50-75% of META's 1223.16%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
615.50%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
615.50%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
275.43%
Below 50% of META's 2770.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
275.43%
5Y net income/share CAGR similar to META's 304.58%. Walter Schloss might see both on parallel mid-term trajectories.
275.43%
3Y net income/share CAGR 1.25-1.5x META's 194.47%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.24%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
23.08%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
72.72%
BV/share growth above 1.5x META's 5.80%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-15.86%
We’re deleveraging while META stands at 0.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
30.68%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
No Data
No Data available this quarter, please select a different quarter.